Last month, we explored four key trends shaping the biopharma industry in 2025. In this follow-up, we spotlight the evolving role of multi-omics analysis—a field rapidly transforming how diseases are understood, diagnosed, and treated.
In 2024, the global multi-omics market was valued at $2.72 billion and is projected to reach $9.91 billion by 2033, growing…
Introducing the third installment of our recently launched Complimentary Exclusive Video Interview. Jonathan Usuka, Chief Business Officer at Sapient, highlighted Sapient’s high throughput proteomics and metabolomics capabilities to generate multi-omics data and the analytical power to transcend the genome to achieve robust biological discoveries in expediting clinical studies.
By leveraging Sapient's real-world data asset, the…
PharmaShots had its third interview for the “Spotlight- Company of the Month- Metabolon’’. The interview was with Rohan (Ro) F. Hastie, President & CEO at Metabolon where he shared insights from the journey, products, solutions, technologies, and upcoming plans of Metabolon. Metabolon develops analytical methods and software for biomarker discovery by using metabolomics. The company…
Shots:
Karl spoke on Metabolon’s partnership with the University of Oxford Parkinson’s Disease Centre (OPDC) to identify new metabolomic biomarkers for the advancement of Parkinson’s research
Karl also talked about the metabolomic changes which occur in Parkinson’s disease and how Metabolon will support OPDC's mission to improve research and understanding of the biology of early…

